150 related articles for article (PubMed ID: 38578519)
1. Pathogenic Aspergillus Strains Identification and Antifungal Susceptibility Analysis of 452 Cases with Otomycosis in Jingzhou, China.
Peng D; Li A; Kong M; Mao C; Sun Y; Shen M
Mycopathologia; 2024 Apr; 189(2):30. PubMed ID: 38578519
[TBL] [Abstract][Full Text] [Related]
2. Species identification and antifungal susceptibility testing of Aspergillus strains isolated from patients with otomycosis in northern China.
Jing R; Yang WH; Xiao M; Li Y; Zou GL; Wang CY; Li XW; Xu YC; Hsueh PR
J Microbiol Immunol Infect; 2022 Apr; 55(2):282-290. PubMed ID: 33839057
[TBL] [Abstract][Full Text] [Related]
3. Molecular Identification and In Vitro Antifungal Susceptibility of Aspergillus Isolates Recovered from Otomycosis Patients in Western China.
Zhang L; Wang X; Houbraken J; Mei H; Liao W; Hasimu H; Liu W; Deng S
Mycopathologia; 2020 Jun; 185(3):527-535. PubMed ID: 32346838
[TBL] [Abstract][Full Text] [Related]
4. Aspergillus welwitschiae; an otomycosis predominant agent, new epidemiological and antifungal susceptibility data from Iran.
Halvaeezadeh M; Jalaee GA; Fatahinia M; Mahmoudabadi AZ
Microb Pathog; 2023 Aug; 181():106180. PubMed ID: 37257666
[TBL] [Abstract][Full Text] [Related]
5. The Molecular Identification and Antifungal Susceptibilities of Aspergillus Species Causing Otomycosis in Tochigi, Japan.
Hagiwara S; Tamura T; Satoh K; Kamewada H; Nakano M; Shinden S; Yamaguchi H; Makimura K
Mycopathologia; 2019 Feb; 184(1):13-21. PubMed ID: 30291485
[TBL] [Abstract][Full Text] [Related]
6. Species identification and in vitro antifungal susceptibility testing of Aspergillus section Nigri strains isolated from otomycosis patients.
Kamali Sarwestani Z; Hashemi SJ; Rezaie S; Gerami Shoar M; Mahmoudi S; Elahi M; Bahardoost M; Tajdini A; Abutalebian S; Daie Ghazvini R
J Mycol Med; 2018 Jun; 28(2):279-284. PubMed ID: 29540288
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
8. Molecular identification and antifungal susceptibilities of black Aspergillus isolates from otomycosis cases in Hungary.
Szigeti G; Kocsubé S; Dóczi I; Bereczki L; Vágvölgyi C; Varga J
Mycopathologia; 2012 Aug; 174(2):143-7. PubMed ID: 22359155
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of terbinafine and itraconazole against Aspergillus species isolated from otomycosis.
Karaarslan A; Arikan S; Ozcan M; Ozcan KM
Mycoses; 2004 Aug; 47(7):284-7. PubMed ID: 15310330
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Combination of Terbinafine with Ketoconazole Against Aspergillus Species with Terbinafine High MIC Values Isolated From Otomycosis.
Nosratabadi M; Espahbodi A; Hedayati MT; Shokohi T; Badali H; Saeedi M; Moazeni M; Aghili SR; Javidnia J; Faeli L; Khojasteh S; Roohi B; Abbasi K; Abastabar M; Haghani I
Mycopathologia; 2023 Apr; 188(1-2):119-127. PubMed ID: 36449121
[TBL] [Abstract][Full Text] [Related]
11. Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.
Kiakojuri K; Mahdavi Omran S; Roodgari S; Taghizadeh Armaki M; Hedayati MT; Shokohi T; Haghani I; Javidnia J; Kermani F; Badali H; Abastabar M
Mycopathologia; 2021 May; 186(2):245-257. PubMed ID: 33718990
[TBL] [Abstract][Full Text] [Related]
12. Species assignment and antifungal susceptibilities of black aspergilli recovered from otomycosis cases in Iran.
Szigeti G; Sedaghati E; Mahmoudabadi AZ; Naseri A; Kocsubé S; Vágvölgyi C; Varga J
Mycoses; 2012 Jul; 55(4):333-8. PubMed ID: 21895787
[TBL] [Abstract][Full Text] [Related]
13. Lamisil, a potent alternative antifungal drug for otomycosis.
Zarei Mahmoudabadi A; Seifi Z; Gharaghani M
Curr Med Mycol; 2015 Mar; 1(1):18-21. PubMed ID: 28680976
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
Wang HC; Hsieh MI; Choi PC; Wu CJ
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
[TBL] [Abstract][Full Text] [Related]
15. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
[TBL] [Abstract][Full Text] [Related]
17. Antifungal susceptibility profiles of otomycosis etiological agents in Ahvaz, Iran.
Gharaghani M; Halvaeezadeh M; Ali Jalaee G; Taghipour S; Kiasat N; Zarei Mahmoudabadi A
Curr Med Mycol; 2020 Jun; 6(2):18-22. PubMed ID: 33628977
[TBL] [Abstract][Full Text] [Related]
18. Identification of Fungal Pathogens in Otomycosis and Their Drug Sensitivity: Our Experience.
Ali K; Hamed MA; Hassan H; Esmail A; Sheneef A
Int Arch Otorhinolaryngol; 2018 Oct; 22(4):400-403. PubMed ID: 30357045
[No Abstract] [Full Text] [Related]
19. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
Espinel-Ingroff A; Diekema DJ; Fothergill A; Johnson E; Pelaez T; Pfaller MA; Rinaldi MG; Canton E; Turnidge J
J Clin Microbiol; 2010 Sep; 48(9):3251-7. PubMed ID: 20592159
[TBL] [Abstract][Full Text] [Related]
20. Administration of 1% topical voriconazole drops was effective and safe in the treatment of refractory otomycosis without tympanic membrane perforation.
Zhang S; Jin M; Hu S; Zhang Y; Zhou G
Ann Otol Rhinol Laryngol; 2021 Mar; 130(3):273-279. PubMed ID: 32772544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
